Monday, August 2, 2021
wellness India Expo
Home Tags Cipla

Tag: Cipla

Top 5 pharma majors collaborate to conduct clinical trial of anti-viral...

Cipla, Dr. Reddy’s, Emcure, Sun Pharma and Torrent to collaborate for clinical trial of investigational anti-viral drug Molnupiravir for COVID-19...........................

Roche launches antibody cocktail to treat COVID-19, Cipla to market it...

Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk of severe COVID-19.............................

Cipla launches ‘ViraGen’ Covid-19 RT-PCR test

The company has further strengthened its offerings and continues to be at the forefront of COVID care..........................

Cipla signs licensing deal with Lilly to expand access to COVID-19...

Baricitinib was issued a restricted emergency use approval by the CDSCO, Ministry of Health, India for use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults..........................

Cipla signs COVID-19 drug licensing deal with MSD

Cipla enters into a licensing agreement with MSD to expand access to the investigational oral therapeutic drug for COVID-19 treatment...........................

DigiHealth to invest in developing a world-class supply chain & distribution...

The investment has been made with a view to develop a world-class pharmaceutical supply chain & distribution IT ecosystem and support the government’s National Digital Health Mission.............................

Cipla pledges support to ‘Terra Carta’, for a sustainable future

Cipla is the only Indian pharmaceutical company to join this global sustainability initiative........................

1 out of 4 oncologists willing to include palliative care within...

Findings from the Oncologist Survey conducted by Cipla Palliative Care and Training Centre, Pune suggest early integration of palliative care is crucial.......................

CSIR-CDRI & Cipla Foundation partner for a one-of-its-kind research & outreach...

Putting into action, the recent GOI’s provision for CSR funding to support research...................

Cipla launches ‘CIPtest’ rapid antigen detection test for COVID-19 diagnosis

Validated and approved by ICMR, the test is found to have specificity and sensitivity of 98.09% and up to 75% respectively. This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit......................